Summary
Teniposide has been evaluated in a phase II clinical trial in chronic lymphocytic leukemia (CLL). Among 16 consecutive patients with CLL entered in the study and treated with Teniposide, 100 mg/m2 weekly, no objective response was observed. Toxicity was generally mild and mainly hematologic. Teniposide at this dosage and schedule is an inactive drug in CLL.
This is a preview of subscription content, log in via an institution to check access.
References
Chiuten DF, Bennett JM, Creech RH, Glick J, Falson G, Brodovsky HS, Begg CB, Muggia FM, Carbone PP (1974) VM-26, a new anticancer drug with effectiveness in malignant lymphoma: A Eastern Cooperative Oncology Group Study. Cancer Treat Rep 63: 7–11
Miller S, Perotta A (1978) Multiple myeloma results with the M-2 protocol in a community hospital. Blood (Suppl 1) 52: 264
Muggia FM, Selawry OS, Hausen HH (1971) Clinical studies with a new podophillotoxin derivative, epipodophillotoxin, 4'-demethyl-9 (4, 6, -0-2-thenylidene-β-D-glucopyranoside) (NSC-122819) Cancer Chemother Rep 55: 575–581
O'Dwyer PJ, Alonso MT, Leyland-Jones B, Marsoni S (1985) Teniposide: a review of 12 years of experience. Cancer Treat Rep 68: 1455–1466
Oken MM, Kaplan ME (1979) Combination chemotherapy with cyclophosphalmide, vincristine and prednisone in the treatment of refractory chronic lymphocytic leukemia. Cancer Treat Rep 63: 441–447
Tirelli U, Carbone A, Tumolo S, Galligioni E, Veronesi A, Trovò MG, Grigoletto E (1981) VM-26 in advanced Mycosis Fungoides. Tumori 67: 487–490
Tirelli U, Carbone A, Franchini G, Galligioni E, Veronesi A, Trovò MG, Volpe R, Tumolo S, Grigoletto E (1982) VM-26 in malignant hematological disease a phase II study. Cancer Chemother Pharmacol 7: 173–174
Tirelli U, Carbone A, Crivellari D, Volpe R, Franchini G, Veronesi A, Galligioni E, Trovò MG, Tumolo S, Grigoletto E (1984) A phase II trial of tenoposide (VM-26) in advanced non-Hodgkin's lymphoma, with emphasis on the treatment of elderly patients. Cancer 54: 393–396
Tirelli U, Franchini G, Crivellari D, Galligioni E, Veronesi A, Trovò MG, Talamini R, Tumolo S, Grigoletto E (1984) Phase II study of VM-26 in extensively pretreated breast cancer. Am J Clin Oncol (CCT) 7: 451–452
Tirelli U, Zagonel V, Veronesi A, Volpe R, Carbone A, Brema F, Grigoletto E (1985) Phase II study of teniposide (VM-26) in multiple myeloma. Am J Clin Oncol (in press)
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Zagonel, V., Tirelli, U., Veronesi, A. et al. Teniposide is not effective in chronic lymphocytic leukemia. Blut 52, 59–61 (1986). https://doi.org/10.1007/BF00320143
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00320143